What Is LL-37?
LL-37 is a naturally occurring 37-amino-acid peptide produced by the human body.
It’s part of a larger protein called:
hCAP18 — human cathelicidin antimicrobial protein 18
When hCAP18 is processed, it releases LL-37.
LL-37 belongs to a family of molecules called antimicrobial peptides, or AMPs.
These peptides are part of the body’s innate immune system—the rapid, first-line defense system that responds before the highly specialized adaptive immune response fully kicks in.
LL-37 is found in places that regularly encounter the outside world, including:
- Skin
- Airways
- Gastrointestinal tract
- Saliva
- Immune cells
- Reproductive tissues
It has attracted enormous research interest because it appears to do considerably more than simply kill microbes.
LL-37 can influence:
microorganisms + inflammation + immune signaling + cell migration + blood-vessel formation + wound repair.
But that complexity also creates a problem.
LL-37 isn’t simply a universally beneficial “immune peptide.”
Depending on the biological situation, too much LL-37 may actually contribute to inflammatory or autoimmune disease.
Why Are Researchers Interested in It?
Most antibiotics work by targeting particular biological structures or processes inside microorganisms.
Antimicrobial peptides such as LL-37 can work differently.
LL-37 is positively charged, allowing it to interact with negatively charged microbial membranes.
In simplified terms:
LL-37 approaches the membrane → interacts with it → disrupts its structure → the microorganism may lose membrane integrity.
This broad mechanism has generated interest in LL-37 as researchers search for new ways to address antimicrobial resistance.
But membrane disruption is only part of the story.
LL-37 also acts as an immune signaling molecule.
That’s where things become especially interesting.
How Does LL-37 Work?
LL-37 has several proposed and demonstrated biological activities.
Direct antimicrobial activity
It can interact with and disrupt microbial membranes.
Immune signaling
It can influence immune cells and inflammatory pathways.
Chemotaxis
LL-37 can help attract certain immune cells toward areas of injury or infection.
Wound repair
It can influence keratinocytes, epithelial cells, cell migration and blood-vessel formation.
Biofilm activity
Researchers have investigated LL-37’s ability to interfere with bacterial biofilms.
Nucleic-acid interactions
LL-37 can bind DNA and RNA and alter how the immune system responds to those molecules.
That final mechanism is especially important because it helps explain why LL-37 may be beneficial in some contexts but harmful in others.
Does LL-37 Kill Bacteria?
In laboratory experiments:
Yes.
LL-37 has demonstrated activity against numerous bacteria, including both Gram-positive and Gram-negative organisms.
Researchers have investigated activity involving organisms such as:
- Staphylococcus aureus
- Pseudomonas aeruginosa
- Escherichia coli
- Other clinically relevant bacteria
This is one reason LL-37 is frequently described as a natural antibiotic peptide.
But that’s a slightly dangerous phrase.
Something demonstrating antimicrobial activity in a laboratory doesn’t mean administering synthetic LL-37 to a person is equivalent to using a clinically validated antibiotic.
Concentration, tissue environment, degradation, delivery, toxicity and interactions with proteins can dramatically alter antimicrobial activity inside the human body.
What About Antibiotic-Resistant Bacteria?
This is a legitimate and exciting area of research.
Antibiotic resistance is a major global health problem, and antimicrobial peptides offer researchers potential strategies that differ from conventional antibiotics.
LL-37 and molecules inspired by LL-37 are therefore being investigated for activity against drug-resistant microorganisms.
Researchers are also developing modified LL-37 fragments and synthetic antimicrobial peptides intended to retain useful antimicrobial properties while reducing toxicity or improving stability.
That may ultimately be more promising therapeutically than simply administering native LL-37 itself.
What About Biofilms?
Biofilms are organized communities of microorganisms surrounded by a protective extracellular matrix.
They’re one reason some infections become difficult to eliminate.
Biofilms can develop on:
wounds + teeth + medical devices + tissues + implanted materials.
LL-37 has demonstrated interesting anti-biofilm activity, including effects at concentrations below those needed to directly kill bacteria.
A well-known study involving Pseudomonas aeruginosa found that LL-37 could inhibit biofilm formation and influence bacterial behaviors involved in biofilm development.
That makes biofilm research a legitimate search category for LL-37.
It doesn’t establish synthetic LL-37 as a clinically proven biofilm treatment.
Does LL-37 Kill Fungi?
LL-37 has demonstrated antifungal activity in experimental research as well.
That includes research involving Candida species.
This is why LL-37 sometimes appears in discussions about:
Candida + fungal infections + microbiome health.
But once again, laboratory antifungal activity isn’t evidence that LL-37 treats candidiasis in humans.
What About Viruses?
LL-37 also has antiviral research behind it.
Studies have investigated its interactions with multiple viruses and possible mechanisms including:
- Direct interaction with viral particles
- Disruption of viral envelopes
- Interference with cellular entry
- Modulation of antiviral immune responses
Research interest expanded substantially during the COVID-19 era because vitamin D, cathelicidin biology and respiratory innate immunity were already interconnected research areas.
But LL-37 is not an established antiviral treatment, and evidence shouldn’t be interpreted as showing it treats influenza, COVID-19, herpes or other viral infections.
What Does Vitamin D Have to Do With LL-37?
This is one of the more interesting pieces of LL-37 biology.
The gene responsible for producing human cathelicidin contains a vitamin D response element.
Activation of the vitamin D receptor can increase expression of cathelicidin/LL-37 in certain cells.
This helped researchers identify an important connection between:
vitamin D → innate immunity → antimicrobial peptide production.
Human macrophage research demonstrated that vitamin D receptor signaling can promote antimicrobial responses involving cathelicidin.
But this does not mean taking massive amounts of vitamin D creates unlimited LL-37 or prevents infections.
It’s a regulatory relationship, not a reason for megadosing vitamin D.
What About Wound Healing?
This is another major area of LL-37 research.
LL-37 isn’t only antimicrobial.
It can influence processes required during tissue repair, including:
keratinocyte migration + epithelial repair + angiogenesis + immune-cell recruitment.
Researchers have found LL-37 expression in healing human skin and experimental evidence suggesting it contributes to re-epithelialization.
When LL-37 activity was blocked experimentally, wound closure was impaired.
That makes LL-37 especially interesting because wounds require the body to solve two problems simultaneously:
prevent infection + rebuild damaged tissue.
LL-37 potentially participates in both.
What About Chronic Wounds?
Researchers have investigated LL-37 and related antimicrobial peptides in:
- Diabetic wounds
- Chronic ulcers
- Infected wounds
- Burns
- Impaired wound healing
Chronic wounds frequently involve a complicated mixture of:
poor tissue repair + inflammation + bacteria + biofilms + vascular problems.
A peptide influencing several of those systems simultaneously is scientifically attractive.
But native LL-37 itself hasn’t become an established routine treatment for chronic wounds.
What About Skin?
Skin is one of the most important places LL-37 functions naturally.
Keratinocytes can produce antimicrobial peptides in response to:
injury + infection + inflammation.
That makes LL-37 relevant to research involving:
- Skin barrier function
- Wound healing
- Infection
- Acne
- Rosacea
- Psoriasis
- Atopic dermatitis
- Chronic wounds
But this is where LL-37’s biology gets particularly complicated.
Because sometimes more LL-37 isn’t better.
What About Rosacea?
Rosacea provides one of the clearest examples.
Research has found abnormally high levels and altered processing of cathelicidin peptides in rosacea-affected skin.
A landmark study showed that patients with rosacea had abnormal cathelicidin expression and processing, and experimentally increasing related activity produced rosacea-like inflammation in mice.
So LL-37 can participate in inflammatory skin disease.
That’s a very important counterweight to the idea that LL-37 is simply an “anti-inflammatory healing peptide.”
What About Psoriasis?
Psoriasis gives us an even more fascinating example.
LL-37 can bind fragments of the body’s own DNA released from damaged cells.
Normally, extracellular self-DNA doesn’t trigger a major immune reaction.
But LL-37 can form complexes with that DNA and deliver it to immune cells called plasmacytoid dendritic cells.
Those cells may then respond as though they’re detecting a threat.
Research identified this LL-37/self-DNA mechanism as an important contributor to autoimmune inflammation in psoriasis.
So in psoriasis:
LL-37 may actually help drive inappropriate immune activation.
That’s why calling it an “immune-boosting peptide” is far too simplistic.
What About Autoimmune Disease?
LL-37 has been investigated across several autoimmune and inflammatory diseases.
Its ability to bind nucleic acids and influence innate immune receptors creates potential connections with:
- Psoriasis
- Lupus
- Rheumatoid arthritis
- Other autoimmune conditions
This doesn’t mean LL-37 causes all these diseases.
It means dysregulated LL-37 signaling may participate in certain disease mechanisms.
And it raises a very important question about therapeutic supplementation:
If LL-37 can amplify particular inflammatory pathways, would giving additional LL-37 always be desirable?
Clearly, we can’t assume that.
Is LL-37 Anti-Inflammatory or Pro-Inflammatory?
Potentially both.
That’s one of the most important things to understand about LL-37.
Its effects depend on:
concentration + tissue + immune environment + interacting molecules + receptors + disease state.
LL-37 can neutralize some bacterial inflammatory products and support normal immune defense.
But it can also stimulate immune signaling, recruit immune cells and amplify inflammation in certain circumstances.
So describing LL-37 simply as an:
“anti-inflammatory peptide”
is inaccurate.
It’s better described as an immunomodulatory peptide.
What About the Gut?
LL-37 and other antimicrobial peptides are part of the body’s defense system at mucosal surfaces, including the gastrointestinal tract.
Researchers investigate them in relation to:
- Intestinal immunity
- Microbial defense
- Gut barrier function
- Inflammatory bowel disease
- Microbiome interactions
But there isn’t strong clinical evidence establishing synthetic LL-37 as a treatment for:
Crohn’s disease, ulcerative colitis, IBS or “leaky gut.”
Those belong in our discovery keywords because of the underlying research—not because they’re proven indications.
What About Lyme Disease?
This is worth including because people searching research peptides frequently encounter claims about LL-37 and Lyme disease.
LL-37’s broad antimicrobial biology makes it easy to understand how these claims develop.
But there isn’t convincing clinical evidence demonstrating that administering LL-37 treats human Lyme disease.
Someone searching “LL-37 Lyme” should absolutely find this page.
What they should then find is the distinction between:
antimicrobial activity in experimental systems
and
a clinically proven treatment for a specific infection.
What About Cancer?
LL-37 has also been investigated extensively in cancer biology.
And once again, the story is complicated.
Depending on cancer type and biological context, LL-37 signaling has been associated with both:
tumor-promoting and potentially antitumor effects.
LL-37 can influence:
- Cell proliferation
- Angiogenesis
- Immune responses
- Cell migration
- Tumor microenvironment signaling
This is another reason indiscriminately describing LL-37 as a universally beneficial healing molecule isn’t scientifically justified.
Evidence Snapshot
Natural Human Biology: Very well established
Laboratory Research: Extensive
Animal Research: Extensive
Human Tissue Research: Yes
Antibacterial Activity: Strong laboratory evidence
Antifungal Activity: Laboratory evidence
Antiviral Research: Yes
Biofilm Research: Yes
Wound-Healing Research: Substantial preclinical evidence
Immune-Modulation Research: Extensive
Human Therapeutic Trials of LL-37: Limited
Established Treatment for Chronic Infection: No
Established Autoimmune Treatment: No
FDA Approved: No
Overall Evidence: Extremely interesting natural immune biology and substantial preclinical research, but limited evidence supporting synthetic LL-37 as a broadly effective human therapy.
What Do We Know?
LL-37 is a genuine human antimicrobial peptide.
It’s an important component of innate immunity and can participate in:
microbial defense → immune signaling → cell recruitment → epithelial repair → wound healing.
It has demonstrated activity against numerous microorganisms in experimental systems and has fascinating effects on bacterial biofilms.
We also know that LL-37’s activity can become dysregulated.
Research involving rosacea and psoriasis demonstrates that LL-37 can participate in inflammatory disease rather than simply suppressing it.
That dual nature is essential to understanding this peptide.
What Don’t We Know?
We don’t have good evidence establishing synthetic LL-37 as a treatment that:
- Cures bacterial infections
- Replaces antibiotics
- Treats antibiotic-resistant infections
- Eliminates biofilms in humans
- Treats Candida
- Treats systemic fungal infections
- Treats Lyme disease
- Treats viral infections
- Treats COVID-19
- Treats chronic wounds
- Treats Crohn’s disease
- Treats ulcerative colitis
- Treats autoimmune disease
- Improves every inflammatory condition
- Prevents cancer
- Treats cancer
- “Boosts” immunity safely
- Is safe for long-term systemic administration
Many of these areas have research relevance.
That’s not the same as clinical validation.
What About Safety?
Safety is particularly important with LL-37 because its biology is so broad.
LL-37 can interact with:
cell membranes + immune receptors + DNA + RNA + inflammatory pathways.
At higher concentrations, antimicrobial peptides may also produce cytotoxic effects against mammalian cells.
And the inflammatory/autoimmune findings discussed above demonstrate why increasing LL-37 activity isn’t automatically beneficial.
Human systemic safety data for exogenous LL-37 remain limited.
Research-market products introduce additional questions involving:
- Purity
- Sterility
- Peptide aggregation
- Contaminants
- Manufacturing consistency
- Actual peptide concentration
So LL-37’s status as a naturally occurring human peptide doesn’t make externally administered synthetic LL-37 inherently safe.
Research & Regulatory Status
LL-37 is not an FDA-approved medication.
Its biological role is well established, but there is no FDA-approved LL-37 drug with established indications for infection, wound healing, autoimmune disease, gastrointestinal disease, Lyme disease, or immune enhancement.
Most therapeutic claims surrounding research-market LL-37 therefore extend considerably beyond the clinical evidence.
Your Pep Resource Takeaway
LL-37 is one of the coolest peptides in this library because the underlying biology is absolutely real.
Your body actually makes it.
And it sits right at the intersection of:
microbes + immunity + inflammation + skin + wound repair.
Laboratory research shows legitimate antibacterial, antifungal, biofilm and immune effects, while wound research suggests LL-37 can participate in normal tissue repair.
But LL-37 also demonstrates why “more immune activity” isn’t automatically better.
The same peptide involved in protecting us from microorganisms can participate in abnormal inflammation when its signaling becomes dysregulated.
Research in psoriasis is a perfect example: LL-37 can bind the body’s own DNA and help trigger inappropriate immune activation.
So the internet version—
“LL-37 kills pathogens, destroys biofilms and boosts immunity.”
—is missing half the story.
The scientifically interesting version is much better:
LL-37 is a powerful natural immune-regulating peptide whose effects can be protective, inflammatory, antimicrobial, and tissue-repairing depending on the biological context.
That’s precisely why it’s worth researching—and why it shouldn’t be treated like a universal infection-fighting peptide.
Research Areas / Search Keywords
LL-37, LL37, LL 37, cathelicidin, cathelicidin peptide, human cathelicidin, hCAP18, CAP18, antimicrobial peptide, antimicrobial peptides, AMP, innate immunity, innate immune system, immune defense, immune health, immune function, immune response, immunomodulation, immunomodulatory peptide, immune peptide, infection research, bacterial infection research, antibacterial peptide, natural antibiotic research, antibiotic resistance, antimicrobial resistance, drug-resistant bacteria, resistant infections, MRSA research, Staphylococcus aureus, Staph, Pseudomonas aeruginosa, E. coli, Escherichia coli, biofilm, biofilms, biofilm research, bacterial biofilm, chronic infection research, fungal research, antifungal peptide, Candida, Candida albicans, Candida research, yeast research, viral research, antiviral peptide, antiviral research, respiratory infection research, COVID research, coronavirus research, influenza research, herpes research, Lyme disease research, Lyme research, Borrelia research, wound healing, wound repair, wound infection, chronic wounds, diabetic wounds, diabetic ulcers, skin ulcers, pressure ulcers, burns, burn healing research, tissue repair, tissue regeneration, epithelial repair, re-epithelialization, keratinocytes, angiogenesis, blood vessel formation, skin health, skin barrier, skin immunity, skin infection, inflammatory skin conditions, rosacea, rosacea research, psoriasis, psoriasis research, eczema research, atopic dermatitis research, dermatitis, acne research, inflammation, chronic inflammation, inflammatory signaling, cytokines, chemotaxis, immune-cell migration, autoimmune research, autoimmune disease, lupus research, rheumatoid arthritis research, self-DNA, DNA immune signaling, plasmacytoid dendritic cells, Toll-like receptors, TLR research, gut health, intestinal immunity, gastrointestinal health, gut barrier, intestinal barrier, microbiome, gut microbiome, Crohn’s disease research, ulcerative colitis research, IBD research, inflammatory bowel disease, leaky gut research, vitamin D, vitamin D immunity, vitamin D antimicrobial peptides, cancer research, tumor biology, tumor microenvironment, angiogenesis research, healing peptides, immune peptides, antimicrobial peptide therapy, synthetic LL-37.
Educational Disclaimer: This profile is provided for educational and research-information purposes only. It is not medical advice and does not provide dosing, administration, infection treatment, or purchasing recommendations. LL-37 is a naturally occurring human antimicrobial peptide, but synthetic LL-37 is not an FDA-approved treatment for infection, autoimmune disease, wound healing, gastrointestinal disease, or other conditions.